Carcinogenesis, Vol. 23, No. 11, 1811-1819,
November 2002
© 2002 Oxford University Press
CANCER BIOLOGY |
Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase
1 Department of Medicine, University of Colorado School of Medicine, CU Cancer Center, and Denver Health Medical Center, Denver, CO 80204, USA,
2 Division of Neurosurgery, The First Affiliated Teaching Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China and
3 Division of Cancer Diagnosis and Treatment, Jinhua Guangfu Hospital, Jinhua, Zhejiang, People’s Republic of China
The receptor tyrosine kinase RON (recepteur d’origine nantais), a member of the MET proto-oncogene family, has been implicated in the pathogenesis of certain epithelial cancers including lung adenocarcinomas. To determine the oncogenic potential of RON, transgenic mice were generated using the surfactant protein C promoter to express human wild-type RON in the distal lung epithelial cells. The mice were born normal without morphological defects in the lung, however, multiple lung adenomas with distinct morphology and growth pattern were observed. Tumors appeared as a single mass in the lung around 2 months of age and gradually developed into multiple nodules throughout the lung. Most of the tumors were characterized as cuboidal epithelial cells with type II cell phenotypes. They grew along the alveolar walls and projected into the alveolar septa. A transition from pre-malignant adenomas to adenocarcinomas was observed. The RON transgene is highly expressed and constitutively activated in the tumors as evident by immunohistochemical staining and western blot analyses. Moreover, we found that Ras expression was dramatically increased in the majority of tumors. However, no mutation in the ‘hot spots’ of the K-Ras or p53 gene was observed, although limited genomic instability occurs in individual tumors. Taken together, this is a mouse lung tumor model with unique biological characteristics. The model may provide an opportunity to study the role of RON in lung tumors and to elucidate the mechanisms underlying this distinct lung tumor.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. M. Thomas, K. Toney, C. Fenoglio-Preiser, M. P. Revelo-Penafiel, S. R. Hingorani, D. A. Tuveson, S. E. Waltz, and A. M. Lowy The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression Cancer Res., July 1, 2007; 67(13): 6075 - 6082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Bhatt, A. Welm, C. J. Farady, M. Vasquez, K. Wilson, and C. S. Craik Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway PNAS, April 3, 2007; 104(14): 5771 - 5776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. O'Toole, K. E. Rabenau, K. Burns, D. Lu, V. Mangalampalli, P. Balderes, N. Covino, R. Bassi, M. Prewett, K. J. Gottfredsen, et al. Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member. Cancer Res., September 15, 2006; 66(18): 9162 - 9170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Wang, D. Wang, and Y.-Q. Chen Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase Carcinogenesis, August 1, 2003; 24(8): 1291 - 1300. [Abstract] [Full Text] [PDF]
|
|